Bob Brigham
RawstoryFri, 27 Nov 2020 16:16 UTC
© REUTERS / Charles Platiau; REUTERS / George Frey
The scandal over major corporations causing an overdose crisis expanded on Friday with a bombshell report in The New York Times
."When Purdue Pharma agreed last month to plead guilty to criminal charges involving OxyContin, the Justice Department noted the role an unidentified consulting company had played in driving sales of the addictive painkiller even as public outrage grew over widespread overdoses," the newspaper
reported.
"Documents released last week in a federal bankruptcy court in New York show that the adviser was McKinsey & Company, the world's most prestigious consulting firm."McKinsey reportedly had a plan to reimburse distributors every time one of their customers was killed by OxyContin.
"In a 2017 presentation, according to the records, which were filed in court on behalf of multiple state attorneys general, McKinsey laid out several options to shore up sales. One was to give Purdue's distributors a rebate for every OxyContin overdose attributable to pills they sold,"
The Times reported.
"The presentation estimated how many customers of companies including CVS and Anthem might overdose. It projected that in 2019, for example, 2,484 CVS customers would either have an overdose or develop an opioid use disorder. A rebate of $14,810 per 'event' meant that Purdue would pay CVS $36.8 million that year."
CVS and Anthem denied receiving rebates.
Comment: From
RT:
It is reported that in a 2017 presentation, McKinsey laid out several suggestions for boosting sales of the pill, including by compensating distributors the damage from selling the product. It estimated the number of people who may overdose or get hooked on OxyContin and suggested paying rebates for "events" that could be reliably attributed to it.
For example, the report explains, a rebate of $14,810 for each of the 2,484 cases - which the consultancy firm projected would happen in 2019 due to OxyContin sold through CVS Health's pharmacy chain - would net the distributor $36.8 million. CVS and another firm mentioned in the presentation, Anthem, are among McKinsey's biggest clients. Both companies said they never received any rebates under a scheme described in the court papers.
It is said that senior McKinsey partners also discussed in 2018 doing more than "eliminating all our documents and emails." The suggestion was reportedly floated by Martin Elling, a leader for McKinsey's North American pharmaceutical practice, in response to the news that the state of Massachusetts had sued a former Purdue board member for her role in fueling the opioid crisis. Elling's addressee, Arnab Ghatak, responded as quoted: "Thanks for the heads up. Will do." It's not clear if any records were actually destroyed by McKinsey.
The report also highlights McKinsey's role in persuading the Sacklers family, who own Purdue, to accept their plan to "turbocharge" the sales of OxyContin and in preparing Purdue executives on how to push back against the US Food and Drug Administration.
The firm's involvement in Purdue's predatory business became public knowledge last year, after unredacted legal papers in the Massachusetts case were released. McKinsey has not been charged by the federal government or sued by anyone for consulting Purdue.
The New York Times story was met with disgust and anger online, with many commenters describing the money making advice as nothing short of "evil." The same word was used by an expert cited by the newspaper.
"This is the banality of evil, M.B.A. edition," Anand Giridharadas, a former McKinsey consultant who reviewed the documents, said of the firm's work with Purdue.
"They knew what was going on. And they found a way to look past it, through it, around it, so as to answer the only questions they cared about: how to make the client money and, when the walls closed in, how to protect themselves."
Comment: From RT: